Skip to content
Peptigraph home

Cagrilintide

Amylin analog. Cagrilintide is investigational and not approved for any use.

Also called:cagricag
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusInvestigational (CagriSema component)Prohibited by WADA (S0)Full legal history

Key facts

How we verify
Class
Amylin analog
Also called
cagri, cag
Vial sizes sold
2.5 mg, 5 mg, 10 mg
Community-reported sizes
Half-life
159-195 h (with semaglutide 2.4 mg co-administered)
subcutaneous, in people · Lancet 2021, PMID 33894838
FDA status
Not approved
Investigational (CagriSema component)
WADA
Prohibited (S0)
In and out of competition
Everything on Cagrilintide

Cagrilintide guides

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.Half-lifeWhat is measured, by route, and what is not.For weight lossWhat research says about Cagrilintide for weight loss.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Cagrilintide: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight lossNot in our ledgerNot in our ledger4Human RCT evidence, 4 of 4Lancet 2021, PMID 34798060

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Compared with

CagrilintidevsRetatrutideAmylin analog next to GLP-1 / GIP / glucagon triple agonist: evidence, dosing and legal status side by side.Investigational · phase 3Read the comparison →CagrilintidevsTirzepatideAmylin analog next to GLP-1 / GIP dual agonist: evidence, dosing and legal status side by side.FDA approved (Mounjaro, Zepbound)Read the comparison →

Common stacks

Cagrilintide is often sold pre-mixed or combined with other peptides. A few of these pairs appear together in published studies; each stack page lists what was tested, and the pages below cover the math and what each part has been studied for.

Cagrilintide + RetatrutideCagrilintide + TirzepatideCagrilintide + Semaglutide

Common questions

Is Cagrilintide FDA approved?

No. Cagrilintide is investigational (investigational (cagrisema component)) and not approved for any use.

Is Cagrilintide banned in sport?

Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

Sources

  1. 1US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "cagrilintide" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  4. 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  5. 5Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  6. 6Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  7. 7Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026

Found an error? Report a correction.